CTOs on the Move

Instrumentation Laboratories

www.instrumentationlaboratory.com

 
Instrumentation Laboratories is a Bedford, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 250-1000
  • Annual Revenue: $250-500 Million

Executives

Name Title Contact Details

Similar Companies

PNP Therapeutics

PNP Therapeutics is a Birmingham, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Rain Therapeutics

Rain Therapeutics is a clinical-stage precision oncology company. Our uncompromised dream is to develop and implement the best precision oncology therapies for patients suffering from cancer. We are rooted in this purpose — extending the quality and length of life for cancer patients where we may be their best hope.

BioGenex Laboratories, Inc.

BioGenex Laboratories, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Pennsylvania Environmental

Pennsylvania Environmental is a Philadelphia, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Switch Therapeutics

Switch Therapeutics is an emerging preclinical stage biotechnology company pioneering a new type of medicine that integrates nucleic acid nanotechnology and RNA interference (RNAi) science with the goal of treating a range of diseases – affecting the central nervous system and systemic indications – with significant unmet needs. Switch`s novel gene knockdown approach is based on technology developed by renowned researchers in the field of RNA from Caltech, Harvard and City of Hope. Based on the scientific discovery of Switch`s co-founders, the company has developed a novel proprietary platform known as CASi (Conditionally Activated siRNAs) that combines advantageous properties of both single and double-stranded RNAs in a single molecule, allowing for cell selective RNAi activity. To date, Switch has raised $52M in funding through Series A, and the company`s South San Francisco based team has continued to grow as its research has advanced.